论文部分内容阅读
目的 观察重组组织型纤溶酶原激活剂 (rt-PA)与尿激酶 (UK)治疗急性心肌梗死 (AMI)的疗效、价值及安全性。方法 6 6例AMI病人均采用静脉溶栓 ,随机分为rt-PA组 (观察组 )和UK组 (对照组 ) ,两组都用肝素。结果 A组与K组相经血管再通率为 76 %、6 3%,差异有显著性。发病 3～ 12h溶栓 ,再通率为 6 2 %、42 %,差异非常显著。除心律失常外 ,其它重症症状发生率不显著。结论 rt-PA溶栓疗效优于UK ,从统计学上分析差异有显著性 ,故临床上rt-PA有推广的必要时 ,尤其对发病时间 >3～ 6h者 ,疗效明显优于UK。
Objective To observe the efficacy, value and safety of recombinant tissue plasminogen activator (rt-PA) and urokinase (UK) in the treatment of acute myocardial infarction (AMI). Methods Six of 6 AMI patients were treated with intravenous thrombolysis and were randomly divided into rt-PA group (observation group) and UK group (control group). Heparin was used in both groups. Results The recanalization rates of group A and group K were 76% and 63%, respectively. The difference was significant. The incidence of 3 ~ 12h thrombolysis, and then pass rate of 62%, 42%, the difference was significant. In addition to arrhythmia, the incidence of other severe symptoms is not significant. Conclusion The curative effect of rt-PA thrombolysis is better than that of UK. There is significant difference statistically in the analysis of rt-PA. Therefore, rt-PA is clinically superior to UK when necessary for promotion, especially for those with onset time> 3 ~ 6h.